Free Trial
NASDAQ:CBLL

CeriBell Q3 2025 Earnings Report

CeriBell logo
$12.99 +0.34 (+2.69%)
Closing price 04:00 PM Eastern
Extended Trading
$12.98 -0.02 (-0.12%)
As of 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CeriBell EPS Results

Actual EPS
N/A
Consensus EPS
-$0.43
Beat/Miss
N/A
One Year Ago EPS
N/A

CeriBell Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CeriBell Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Tuesday, November 11, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

CeriBell Earnings Headlines

Ceribell Expands Supply Chain with New Amendment
Melt-up warning
Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in his urgent broadcast, he names three investments he believes could soar as America’s financial system nears a breaking point.tc pixel
Medtech Leader Erica Rogers Joins Ceribell Board of Directors
See More CeriBell Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CeriBell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CeriBell and other key companies, straight to your email.

About CeriBell

CeriBell (NASDAQ:CBLL) Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows. CeriBell devices typically feature automated test protocols, digital signal processing and connectivity options for integration with electronic health record systems. These diagnostic platforms are engineered to meet regulatory requirements in multiple jurisdictions and are complemented by service contracts and technical support offerings.

CeriBell has developed a global presence through direct sales and distribution partnerships across North America, Europe and select international markets. By collaborating with healthcare providers, clinical laboratories and research institutions, the company focuses on refining screening protocols, delivering training resources and expanding access to early hearing assessment solutions. CeriBell’s commitment to innovation and clinical validation underpins its mission to reduce the incidence of undiagnosed hearing loss in newborns and support positive developmental outcomes in pediatric populations.

View CeriBell Profile

More Earnings Resources from MarketBeat